Last reviewed · How we verify
NCT03908671
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Esophageal Cancer and Non-small Cell Lung Cancer
NA trial testing Personalized mRNA Tumor Vaccine in Esophageal Cancer in 24 participants. Status unknown.
31 October 2024
Quick facts
| Lead sponsor | Stemirna Therapeutics |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 18 October 2019 |
| Primary completion | 31 October 2024 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Personalized mRNA Tumor Vaccine — full drug profile →
Conditions studied
- Esophageal Cancer — all drugs for Esophageal Cancer →
- Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →
Sponsor
Stemirna Therapeutics — full company profile →
Who can join
Adults 18 to 75, any sex, with Esophageal Cancer or Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A single arm, open-label pilot study is designed to determine the safety, tolerability and effectiveness of personalized mRNA tumor vaccine encoding neoantigen in Patients with advanced esophageal cancer and non-small cell lung cancer
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Neoantigens: promising targets for cancer therapy.
Xie N, Shen G, Gao W, Huang Z, et al · · 2023 · cited 713× · PMID 36604431 · DOI 10.1038/s41392-022-01270-x -
Opportunities and Challenges in the Delivery of mRNA-based Vaccines.
Wadhwa A, Aljabbari A, Lokras A, Foged C, et al · · 2020 · cited 410× · PMID 32013049 · DOI 10.3390/pharmaceutics12020102 -
Advances in COVID-19 mRNA vaccine development.
Fang E, Liu X, Li M, Zhang Z, et al · · 2022 · cited 368× · PMID 35322018 · DOI 10.1038/s41392-022-00950-y -
mRNA vaccine: a potential therapeutic strategy.
Wang Y, Zhang Z, Luo J, Han X, et al · · 2021 · cited 286× · PMID 33593376 · DOI 10.1186/s12943-021-01311-z -
Tumor neoantigens: from basic research to clinical applications.
Jiang T, Shi T, Zhang H, Hu J, et al · · 2019 · cited 276× · PMID 31492199 · DOI 10.1186/s13045-019-0787-5 -
mRNA vaccines in disease prevention and treatment.
Zhang G, Tang T, Chen Y, Huang X, et al · · 2023 · cited 148× · PMID 37726283 · DOI 10.1038/s41392-023-01579-1 -
Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives.
Gómez-Aguado I, Rodríguez-Castejón J, Vicente-Pascual M, Rodríguez-Gascón A, et al · · 2020 · cited 144× · PMID 32093140 · DOI 10.3390/nano10020364 -
mRNA cancer vaccines: Advances, trends and challenges.
He Q, Gao H, Tan D, Zhang H, et al · · 2022 · cited 110× · PMID 35345451 · DOI 10.1016/j.apsb.2022.03.011
Verify or expand the search:
- PubMed search for NCT03908671
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Personalized mRNA Tumor Vaccine
Trials testing the same drug.
- NCT03468244 — Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms · NA · unknown
Other recruiting trials for Esophageal Cancer
Currently open trials in the same condition.
- NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
- NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
- NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07307560 — High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients · NA · recruiting
Other Stemirna Therapeutics trials
Trials by the same sponsor.
- NCT05949775 — Clinical Study of mRNA Vaccine in Patients With Advanced Malignant Solid Tumors · NA · unknown
- NCT05911087 — A Phase II/III Study to Evaluate the Immunogenicity and Safety and Efficacy of SWIM816 Vaccines for SARS-CoV-2 · Phase 2, PHASE3 · unknown
- NCT05686161 — mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs · Phase 3 · unknown
- NCT05198752 — A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors · Phase 1 · unknown
- NCT05144139 — A Phase I/II Clinical Trial in Healthy People Aged 18 Years and Above · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03908671 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Stemirna Therapeutics
- Last refreshed: 13 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03908671.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing